Opexa (OPXA) said its T-cell vaccine Tovaxin was safe and effective in a Phase I/II trial in patients with multiple sclerosis. In a 10-patient dose-escalation test, Tovaxin reduced the annualized rate of relapse by 90%. The patients were dosed weekly for 20 weeks and monitored for 32 weeks thereafter. Opexa is enrolling 150 patients into a year-long Phase IIb trial; 100 of the patients will receive Tovaxin in a less-frequent dosing regimen. The endpoint will be the cumulative number of gadolinium-enhancing lesions on T1-weighted MRI scans. Opexa gained 28%, moving up $1.16 to $5.31.
http://biotech.seekingalpha.com/article/31440